Is genetic variability in carboxylesterase-1 and carboxylesterase-2 drug metabolism an important component of personalized medicine?

References

• Bellott R, Le Morvan V, Charasson V, et al. (2008). Functional study of the 830C > G polymorphism of the human carboxylesterase 2 gene. Cancer Chemoth Pharm 61:481–8.
   PubMed Web of Science ®Google Scholar
• Birkus G, Bam RA, Willkom M, et al. (2016). Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors. Antimicrob Agents Ch 60:316–22.
   PubMed Web of Science ®Google Scholar
• Bjerre D, Rasmussen HB, Consortium I. (2017). Novel procedure with improved resolution and specificity for amplification and differentiation of variants of the gene encoding carboxylesterase 1. Pharmacogenet Genom 27:155–8.
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, et al. (2008). The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386–99.
   PubMed Web of Science ®Google Scholar
• Ciliao HL, Camargo-Godoy RBO, Souza MF, et al. (2018). Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil. Mutat Res Genet Tox Envir Muta 836:97–102.
   PubMed Web of Science ®Google Scholar
• Dimatteo C, D'Andrea G, Vecchione G, et al. (2016). Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res 144:1–5.
   PubMed Web of Science ®Google Scholar
• Entresto-PPI. 2018. Novartis Pharmaceutical Corporation, East Hanover, NJ, Entresto (sacubitril and valsartan) [package insert], U.S. Food and Drug Administration.
   Google Scholar
• Fujiyama N, Miura M, Kato S, et al. (2010). Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos 38:2210–7.
   PubMed Web of Science ®Google Scholar
• Fujiyama N, Miura M, Satoh S, et al. (2009). Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Xenobiotica 39:407–14.
   PubMed Web of Science ®Google Scholar
• Furihata T, Hosokawa M, Fujii A, et al. (2005). Dexamethasone-induced methylprednisolone hemisuccinate hydrolase: its identification as a member of the rat carboxylesterase 2 family and its unique existence in plasma. Biochem Pharmacol 69:1287–97.
   PubMed Web of Science ®Google Scholar
• Geshi E, Kimura T, Yoshimura M, et al. (2005). A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res 28:719–25.
   PubMed Web of Science ®Google Scholar
• Hamzic S, Kummer D, Milesi S, et al. (2017). Novel genetic variants in carboxylesterase 1 predict severe Early-Onset Capecitabine-Related toxicity. Clin Pharmacol Ther 102:796–804.
   PubMed Web of Science ®Google Scholar
• Hatfield MJ, Umans RA, Hyatt JL, et al. (2016). Carboxylesterases: General detoxifying enzymes. Chem Biol Interact 259:327–31.
   PubMed Web of Science ®Google Scholar
• He G, Massarella J, Ward P. (1999). Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37:471–84.
   PubMed Web of Science ®Google Scholar
• Horizant-PPI. 2016. Arbor Pharmaceuticals, Atlanta, GA, Horizant (gabapentin enacarbil)[package insert], U.S. Food and Drug Administration.
   Google Scholar
• Hu Y, Epling D, Shi J, et al. (2018). Effect of biphenyl hydrolase-like (BPHL) gene disruption on the intestinal stability, permeability and absorption of valacyclovir in wildtype and Bphl knockout mice. Biochem Pharmacol 156:147–56.
   PubMed Web of Science ®Google Scholar
• Imai T, Taketani M, Shii M, et al. (2006). Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos 34:1734–41.
   PubMed Web of Science ®Google Scholar
• Ishizuka T, Yoshigae Y, Murayama N, Izumi T. (2013). Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Drug Metab Dispos 41:1888–95.
   PubMed Web of Science ®Google Scholar
• Kamendulis LM, Brzezinski MR, Pindel EV, et al. (1996). Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther 279:713–7.
   PubMed Web of Science ®Google Scholar
• Khanna R, Morton CL, Danks MK, Potter PM. (2000). Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 60:4725–8.
   PubMed Web of Science ®Google Scholar
• Kleingeist B, Bocker R, Geisslinger G, Brugger R. (1998). Isolation and pharmacological characterization of microsomal human liver flumazenil carboxylesterase. J Pharm Pharm Sci 1:38–46.
   PubMedGoogle Scholar
• Kobayashi Y, Fukami T, Shimizu M, et al. (2012). Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. Drug Metab Dispos 40:1080–4.
   PubMed Web of Science ®Google Scholar
• Kurokawa T, Fukami T, Yoshida T, et al. (2016). Arylacetamide deacetylase is responsible for activation of prasugrel in human and dog. Drug Metab Dispos 44:409–16.
   PubMed Web of Science ®Google Scholar
• Laizure SC, Parker RB, Herring VL, et al. (2014). Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab Dispos 42:201–6.
   PubMed Web of Science ®Google Scholar
• Lam SW, van der Noort V, van der Straaten T, et al. (2018). Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. Pharmacol Res 128:122–129.
   Google Scholar
• Lewis JP, Horenstein RB, Ryan K, et al. (2013). The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genom 23:1–8.
   PubMed Web of Science ®Google Scholar
• Li W, Escarpe PA, Eisenberg EJ, et al. (1998). Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Ch 42:647–53.
   PubMed Web of Science ®Google Scholar
• Martin M, Martinez N, Ramos M, et al. (2015). Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. Oncologist 20:111–2.
   PubMed Web of Science ®Google Scholar
• Murakami E, Tolstykh T, Bao H, et al. (2010). Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 285:34337–47.
   PubMed Web of Science ®Google Scholar
• Mutch E, Nave R, McCracken N, et al. (2007). The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 73:1657–64.
   PubMed Web of Science ®Google Scholar
• Nemoda Z, Angyal N, Tarnok Z, et al. (2009). Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology 57:731–3.
   PubMed Web of Science ®Google Scholar
• Noel ZR, Kido K, Macaulay TE. (2017). Selexipag for the treatment of pulmonary arterial hypertension. Am J Health Syst Pharm 74:1135–41.
   PubMed Web of Science ®Google Scholar
• Pare G, Eriksson N, Lehr T, et al. (2013). Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127:1404–12.
   PubMed Web of Science ®Google Scholar
• Pindel EV, Kedishvili NY, Abraham TL, et al. (1997). Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J Biol Chem 272:14769–75.
   PubMed Web of Science ®Google Scholar
• Plavix-PPI. 2010. Bristol-Myers Squibb & Sanofi Aventis Companies, Bridgewater, NT, Plavix (clopidogrel) [package insert], U.S. Food and Drug Adminnistration.
   Google Scholar
• Pradaxa-PPI. 2015. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, Pradaxa (dabigatran etexilate) [package insert], U.S. Food and Drug Administration.
   Google Scholar
• Quinney SK, Sanghani SP, Davis WI, et al. (2005). Hydrolysis of capecitabine to 5'-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther 313:1011–6.
   PubMed Web of Science ®Google Scholar
• Rasmussen HB, Madsen MB, Lyauk YK, et al. (2017). Carboxylesterase 1A2 encoding gene with increased transcription and potential rapid drug metabolism in Asian populations. Drug Metab Pers Ther 32:163–8.
   PubMedGoogle Scholar
• Ribelles N, Lopez-Siles J, Sanchez A, et al. (2008). A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr Drug Metab 9:336–43.
   PubMed Web of Science ®Google Scholar
• Sato Y, Miyashita A, Iwatsubo T, Usui T. (2012). Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver. Drug Metab Dispos 40:902–6.
   PubMed Web of Science ®Google Scholar
• Shen Y, Yan B. (2017). Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxil. J Hepatol 66:660–1.
   PubMed Web of Science ®Google Scholar
• Shi J, Wang X, Eyler RF, et al. (2016a). Association of oseltamivir activation with gender and carboxylesterase 1 genetic polymorphisms. Basic Clin Pharmacol Toxico 119:555–61.
   PubMed Web of Science ®Google Scholar
• Shi J, Wang X, Nguyen J, et al. (2016b). Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation. Drug Metab Dispos 44:554–9.
   PubMed Web of Science ®Google Scholar
• Shi J, Wang X, Nguyen JH, et al. (2016c). Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol 119:76–84.
   PubMed Web of Science ®Google Scholar
• Shi D, Yang J, Yang D, et al. (2006). Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319:1477–84.
   PubMed Web of Science ®Google Scholar
• Stage C, Jurgens G, Guski LS, et al. (2017). The pharmacokinetics of Enalapril in relation to CES1 Genotype in Healthy Danish Volunteers. Basic Clin Pharmacol Toxicol 121:487–92.
   PubMed Web of Science ®Google Scholar
• Sun Z, Murry DJ, Sanghani SP, et al. (2004). Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 310:469–76.
   PubMed Web of Science ®Google Scholar
• Sychev DA, Levanov AN, Shelekhova TV, et al. (2018). The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med 11:127–37.
   PubMed Web of Science ®Google Scholar
• Tang M, Mukundan M, Yang J, et al. (2006). Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467–76.
   PubMed Web of Science ®Google Scholar
• Tarkiainen EK, Backman JT, Neuvonen M, et al. (2012). Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther 92:68–71.
   PubMed Web of Science ®Google Scholar
• Tarkiainen EK, Holmberg MT, Tornio A, et al. (2015a). Carboxylesterase 1 c.428G > A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin Pharmacol Ther 97:650–8.
   PubMed Web of Science ®Google Scholar
• Tarkiainen EK, Tornio A, Holmberg MT, et al. (2015b). Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol 80:1131–8.
   PubMed Web of Science ®Google Scholar
• Thomsen R, Rasmussen HB, Linnet K, et al. (2014). In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors. Drug Metab Dispos 42:126–33.
   PubMed Web of Science ®Google Scholar
• Wang X, Rida N, Shi J, et al. (2017). A comprehensive functional assessment of carboxylesterase 1 nonsynonymous polymorphisms. Drug Metab Dispos 45:1149–55.
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, McDonagh EM, Herbert JM, et al. (2012). Phamacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:414–7.
   PubMed Web of Science ®Google Scholar
• Wickremsinhe E, Bao J, Smith R, et al. (2013). Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure. Pharmaceutics 5:261–76.
   PubMedGoogle Scholar
• Williams ET, Carlson JE, Lai WG, et al. (2011). Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett 5:280–9.
   PubMedGoogle Scholar
• Xermelo-PPI. 2017. Lexicon Pharmaceuticals, Inc., Woodland, TX, Xermelo (telotristat ethtyl) [package insert], U.S. Food and Drug Administration.
   Google Scholar
• Xiao FY, Luo JQ, Liu M, et al. (2017). Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients. Sci Rep 7:7244.
   PubMed Web of Science ®Google Scholar
• Xie C, Ding X, Gao J, et al. (2014). The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. Pharmacogenet Genom 24:204–10.
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Kimura T, Ishii M, et al. (2008). Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites. Biochem Bioph Res Co 369:939–42.
   PubMed Web of Science ®Google Scholar
• Zhang J, Burnell JC, Dumaual N, et al. (1999). Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther 290:314–8.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Appel DI, Johnson JA, et al. (2009). Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol 77:1266–72.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Langaee TY, Gong Y, et al. (2016). CES1P1 variant -816A > C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. Eur J Clin Pharmacol 72:681–7.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Patrick KS, Yuan HJ, et al. (2008). Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 82:1241–8.
   PubMed Web of Science ®Google Scholar
• Zou JJ, Chen SL, Fan HW, et al. (2014). CES1A -816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention. J Cardiovasc Pharm 63:178–83.
   PubMed Web of Science ®Google Scholar